Related Experiment Video
Updated: May 11, 2026
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient
1Saskatoon Cancer Center, University of Saskatchewan, Canada.
Background & Aims:
Animal models for hepatic metastases can facilitate the investigation of lymphokine-activated killer (LAK) cell-based immunotherapy. The aim of this study was to investigate the efficacy of ccM4 antibody-targeted LAK cells in inhibiting hepatic micrometastases.
Methods:
Hepatic micrometastases were generated after the intrasplenic injection of HM7 colon carcinoma cells. TAG72 expression was detected in these hepatic micrometastases using ccM4 antibody. The ccM4 antibody was conjugated onto LAK cells by treatment with 17.5% polyethylene glycol 8000. After the intrasplenic injection of HM7 cells, severe combined immunodeficient mice were randomized into five groups (i-v) and received either 10(7) ccM4-LAK cells plus 1000 U interleukin 2 (IL-2; group i), LAK cells plus 50 micrograms ccM4 and IL-2 (group ii), LAK cells plus IL-2 (group iii), IL-2 alone (group iv), or only phosphate-buffered saline (group v).
Results:
The ccM4-LAK cells retained cytolytic activity and acquired TAG72-binding reactivity. The results showed that group i had significantly fewer hepatic metastases compared with group ii or group iii (P < 0.05) and even fewer hepatic metastases compared with group iv or group v (P < 0.001).
Conclusions:
These results show that ccM4 antibody-targeted LAK cells significantly inhibited tumor growth in vivo; thus, they can be potentially useful in treatment of hepatic micrometastases.
Insights
ccM4 antibody-targeted lymphokine-activated killer (LAK) cells significantly inhibited hepatic micrometastases in mice. This targeted immunotherapy shows potential for treating liver metastases.
Area of Science:
- Immunotherapy
- Oncology
- Cell Biology
Background:
- Animal models are crucial for studying hepatic metastases and developing immunotherapies.
- Lymphokine-activated killer (LAK) cells are a key component in cellular immunotherapy.
- Hepatic micrometastases present a significant challenge in cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of ccM4 antibody-targeted LAK cells in inhibiting hepatic micrometastases.
- To assess the potential of this targeted approach in a preclinical model.
Main Methods:
- Hepatic micrometastases were established in mice using HM7 colon carcinoma cells.
- ccM4 antibody was conjugated to LAK cells to target TAG72-expressing micrometastases.
- Mice received targeted LAK cells, non-targeted LAK cells, or control treatments.
Main Results:
- ccM4-LAK cells maintained cytolytic activity and TAG72-binding capability.
- Targeted ccM4-LAK cells significantly reduced hepatic metastases compared to non-targeted LAK cells and controls.
- A statistically significant reduction in tumor burden was observed with targeted therapy.
Conclusions:
- ccM4 antibody-targeted LAK cells demonstrate significant in vivo efficacy against hepatic micrometastases.
- This targeted immunotherapy approach holds promise for the treatment of liver metastases.
- Further investigation into this targeted LAK cell therapy is warranted.
